Remedium Life

Why is Remedium Lifecare Ltd falling/rising?

As of 23-Jun, Remedium Lifecare Ltd's stock price is rising to 0.31, reflecting a 3.33% increase, driven by a 19.23% gain over the past week. However, it has a year-to-date drop of 58.67% and declining investor participation, indicating potential long-term challenges despite short-term momentum.

As of 23-Jun, Remedium Lifecare Ltd's stock price is rising, currently at 0.31, reflecting a change of 0.01 or 3.33% increase. This upward movement can be attributed to a notable performance over the past week, where the stock has gained 19.23%, significantly outperforming the Sensex, which declined by 0.79% during the same period. Additionally, the stock has been on a consecutive gain streak for the last five days, contributing to its recent rise.<BR><BR>However, it is important to note that despite the recent gains, the stock has experienced substantial declines over longer periods, with a year-to-date drop of 58.67% and a one-year decline of 64.77%. The current price is also lower than the 20-day, 50-day, 100-day, and 200-day moving averages, indicating that while there is short-term momentum, the stock is still facing challenges in the longer term.<BR><BR>Moreover, there has been a significant decrease in investor participation, with delivery volume dropping by 69.16% compared to the five-day average. This decline in trading activity may suggest caution among investors, despite the recent positive price movement. Overall, while the stock is currently rising, it is essential to consider the broader context of its performance and investor sentiment.

Which are the latest news on Remedium Life?

What does Remedium Life do?

Remedium Lifecare Ltd, a Micro Cap company in the Trading & Distributors industry, reported net sales of 111 Cr and a net profit of 9 Cr for September 2025. The company, formerly known as Roxy Exports Limited, was incorporated in 1988 and rebranded in 2020.

Overview: <BR>Remedium Lifecare Ltd operates in the Trading & Distributors industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>The company was incorporated on February 19, 1988, and changed its name from "Roxy Exports Limited" to "Remedium Lifecare Limited" on November 6, 2020, to reflect its new business activities. The most recent quarterly results reported net sales and net profit for September 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 111 Cr (Quarterly Results - Sep 2025) <BR>Net Profit: 9 Cr (Quarterly Results - Sep 2025) <BR>Market Cap: INR 26 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 21 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 10.33 <BR>Return on Equity: 2.02% <BR>Price to Book: 0.26<BR><BR>Contact Details: <BR>Address: Office No 601 Hyder Park, Saki Vihar Road Andheri East Mumbai Maharashtra : 400072 <BR>Email: roxycyclesin@gmail.com <BR>Website: http://www.remlife.com

How big is Remedium Life?

As of 10th June, Remedium Lifecare Ltd has a market capitalization of 26.00 Cr, with recent net sales of 488.75 Cr and a net profit of 11.22 Cr. Shareholder's funds are 43.89 Cr, and total assets are valued at 1,720.31 Cr.

As of 10th June, Remedium Lifecare Ltd has a market capitalization of 26.00 Cr, categorizing it as a Micro Cap company.<BR><BR>For the latest four quarters, the company reported Net Sales of 488.75 Cr and a Net Profit of 11.22 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 43.89 Cr and Total Assets valued at 1,720.31 Cr.

Who are in the management team of Remedium Life?

The management team of Remedium Life includes Maneesha Naresh (Independent Director), Haonsh Santok (Director), Vilas Ramkrishna Lokhande (Whole-time Director), Trupti Bolke (Independent Director), and Dhwani Desai (Company Secretary & Compliance Officer).

The management team of Remedium Life includes the following individuals:<BR><BR>1. Maneesha Naresh - Independent Director<BR>2. Haonsh Santok - Director<BR>3. Vilas Ramkrishna Lokhande - Whole-time Director<BR>4. Trupti Bolke - Independent Director<BR>5. Dhwani Desai - Company Secretary & Compliance Officer<BR><BR>If you need more details about their roles or the company, feel free to ask!

Who are the peers of the Remedium Life?

Remedium Life's peers include Nirav Commercial, Kabsons Industri, Newtrac Foods, Franklin Industries, Gini Silk Mills, Shreenath Paper, NMS Global, and Medico Intercon. NMS Global has the highest 1-year return at 101.06%, while Remedium Life's return is -75.63%.

Peers: The peers of Remedium Life are Nirav Commercial, Kabsons Industri, Newtrac Foods, Franklin Indust., Gini Silk Mills, Shreenath Paper, NMS Global, Medico Intercon.<BR><BR>Quality Snapshot: Below Average management risk is observed at Nirav Commercial, Gini Silk Mills, Shreenath Paper, and Medico Intercon., while Average management risk is found at Kabsons Industri, Newtrac Foods, Franklin Indust., and NMS Global. Growth ratings are Below Average for Nirav Commercial, Newtrac Foods, Gini Silk Mills, Shreenath Paper, and Medico Intercon., while Average growth is noted at Kabsons Industri, Franklin Indust., and NMS Global. Capital Structure is rated as Excellent at Medico Intercon., Good at Kabsons Industri and Franklin Indust., and Below Average at Nirav Commercial, Newtrac Foods, Gini Silk Mills, Shreenath Paper, and NMS Global.<BR><BR>Return Snapshot: NMS Global has the highest 1-year return at 101.06%, while Newtrac Foods has the lowest at -56.07%. Remedium Life's 1-year return of -75.63% is significantly lower than both. Additionally, peers such as Franklin Indust., Gini Silk Mills, Shreenath Paper, Medico Intercon., and Remedium Life have negative six-month returns.

Should I buy, sell or hold Remedium Lifecare Ltd?

When is the next results date for Remedium Lifecare Ltd?

The next results date for Remedium Lifecare Ltd is March 9, 2026.

The next results date for Remedium Lifecare Ltd is scheduled for March 9, 2026.

Are Remedium Life latest results good or bad?

Remedium Lifecare's latest results are mixed but lean negative, with a net profit increase driven by non-operating income, while net sales declined and financial leverage poses significant risks. Overall, concerns about revenue volatility and sustainability overshadow the positive indicators.

The latest results for Remedium Lifecare present a mixed picture, but overall, they lean towards the negative side. In Q2 FY26, the company reported a net profit of ₹8.62 crores, which is an impressive increase of 85.38% quarter-on-quarter. However, this surge in profitability is somewhat misleading, as it heavily relies on non-operating income, which accounted for about 30.61% of the operating profit. <BR><BR>On the other hand, net sales declined by 2.04% from the previous quarter, continuing a troubling trend of revenue volatility. The company's operating profit margin improved to 6.64%, but this follows a history of erratic performance, including a negative operating margin in the previous quarter.<BR><BR>Additionally, the financial health of Remedium Lifecare raises concerns. The company operates with extreme financial leverage, indicated by a net debt-to-equity ratio of 25.97, which poses significant risks. The absence of institutional backing and minimal promoter holding (just 1.13%) further complicates its outlook.<BR><BR>In summary, while there are some positive indicators, such as improved margins and sequential profit recovery, the overall financial stability and sustainability of earnings remain questionable. Therefore, the results can be viewed as more negative than positive, especially considering the company's ongoing challenges and the reliance on non-core income for profitability.

How has been the historical performance of Remedium Life?

For the year ending March 2025, Remedium Life reported an operating income of 405.25 crore and a net profit after tax of 2.13 crore, with an EPS of 0.04. The company faced an operating loss of 1.09 crore before other income and had total liabilities of 1,720.31 crore.

Answer:<BR>The historical performance of Remedium Life for the year ending March 2025 shows a total operating income of 405.25 crore, with a total expenditure of 406.34 crore, resulting in an operating profit (PBDIT) of -1.09 crore. After accounting for other income of 10.80 crore, the operating profit stands at 9.71 crore. The profit before tax is reported at 4.38 crore, leading to a profit after tax of 2.13 crore. The earnings per share (EPS) is 0.04, with a diluted EPS of 0.03. The operating profit margin is -0.27%, while the profit after tax margin is 0.53%. <BR><BR>Breakdown:<BR>Remedium Life's financial results for March 2025 indicate a total operating income of 405.25 crore, which is offset by total expenditures of 406.34 crore, leading to an operating loss of 1.09 crore before considering other income. The company reported other income of 10.80 crore, resulting in an operating profit of 9.71 crore. After accounting for interest expenses of 5.29 crore, the profit before tax is 4.38 crore, with a net profit after tax of 2.13 crore. The company has total liabilities of 1,720.31 crore, with total assets matching this figure, indicating a balanced sheet. Cash flow from operating activities shows a significant outflow of 1,134 crore, while financing activities contributed a net inflow of 1,136 crore, resulting in a slight net cash inflow of 1 crore by the end of the period.

Who are the top shareholders of the Remedium Life?

The top shareholders of Remedium Life are primarily individual investors, holding 87.29% of the shares, with Siddharth Chimanlal Shah being the largest promoter at 1.11%. There are no institutional holdings or pledged promoter shares.

The top shareholders of Remedium Life primarily consist of individual investors, who hold a significant 87.29% of the company's shares. Among the promoters, Siddharth Chimanlal Shah is the one with the highest holding at 1.11%. There are no institutional holdings from mutual funds or foreign institutional investors, and there are no pledged promoter holdings. Overall, the majority of the shares are held by non-institutional investors.

Is Remedium Life overvalued or undervalued?

As of February 17, 2025, Remedium Life's valuation has shifted from fair to risky, indicating overvaluation with a PE ratio of 56.31 and a year-to-date return of -63.63%, significantly underperforming its peers and the market.

As of 17 February 2025, the valuation grade for Remedium Life has moved from fair to risky, indicating a significant deterioration in its perceived value. The company appears to be overvalued, particularly when considering its headline ratios, which include a PE ratio of 56.31, a Price to Book Value of 2.73, and an alarming EV to EBIT of -1114.97. These metrics suggest that investors are paying a premium for earnings that are not being generated, raising concerns about the sustainability of its current valuation.<BR><BR>In comparison to its peers, Remedium Life's valuation stands out unfavorably. For instance, MMTC Ltd. has a PE ratio of 119.39, while PTC India Ltd. boasts a very attractive PE of 9.02, highlighting the disparity in valuation within the industry. Additionally, the company's recent stock performance has been dismal, with a year-to-date return of -63.63%, significantly underperforming the Sensex's 5.56% return during the same period. This further reinforces the notion that Remedium Life is currently overvalued in the market.

What is the technical trend for Remedium Life?

As of June 3, 2025, Remedium Life's technical trend is bearish with moderate strength, supported by bearish Bollinger Bands and moving averages, despite mixed signals from MACD and KST indicators.

As of 3 June 2025, the technical trend for Remedium Life has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. The weekly MACD is mildly bullish, but the monthly MACD is bearish, indicating mixed signals across time frames. The Bollinger Bands are bearish on both weekly and monthly charts, reinforcing the bearish outlook. Daily moving averages also confirm a bearish trend. The KST shows a mildly bullish weekly signal but is bearish monthly, while Dow Theory presents a mildly bearish weekly view and a mildly bullish monthly perspective. Overall, the combination of these indicators suggests a prevailing bearish sentiment in the market for Remedium Life.

What is the bonus history of the Remedium Life?

Remedium Life's recent bonus history includes a 3:1 bonus announced for July 5, 2024, and a previous 9:5 bonus issued on July 28, 2023. This reflects the company's commitment to rewarding shareholders with bonus shares.

Remedium Life has a notable bonus history. The most recent bonus issue was announced as a 3:1 bonus, with an ex-date of July 5, 2024, and a record date of July 6, 2024. Prior to that, on July 28, 2023, the company issued a bonus in the ratio of 9:5, with the record date set for July 29, 2023. This indicates a proactive approach to rewarding shareholders through bonus shares.

Has Remedium Life declared dividend?

No Dividend History Available